Similar to the GC cohort, PRKACA expression in the CRC cohort exhibited enrichment of genes that are associated with β-blockers, conventional chemotherapeutics, and tyrosine kinase inhibitors (Figure 1). Here, PRKACA is linked to colorectal carcinoma.